HIGHLIGHTS
- What: This work explores the combination of pentoxifylline an anti-fibrotic and chitinase 3-like-1 (CHI3L1) inhibitor with conventional chemotherapy to improve NSCLC treatment. Interestingly, the results presented in this study demonstrated that pentoxifylline significantly decreased both CHI3L1 and STAT3 expression levels in the NCI-H460/R cell line. Altogether, this work demonstrated the advantage of combining pentoxifylline with different conventional drug regimens in both sensitive and MDR NSCLC cell lines. The authors are aware that this study has some limitations.
- Who: Beatriz S. Matos and collaborators from the i S, Instituto de Investiga . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.